The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 26, 2022

Filed:

Oct. 11, 2018
Applicants:

Ganymed Pharmaceuticals Gmbh, Mainz, DE;

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-universitat Mainz, Mainz, DE;

Inventors:

Ugur Sahin, Mainz, DE;

Özlem Türeci, Mainz, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/39 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/28 (2013.01); C07K 16/30 (2013.01); G01N 33/57446 (2013.01); G01N 33/57488 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/90 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.


Find Patent Forward Citations

Loading…